查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994158

神经性厌食症市场：依治疗方法、疗法、年龄层和最终用户划分－2026-2032年全球市场预测

Anorexia Nervosa Market by Treatment Type, Therapy Type, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经性厌食症市场价值将达到 1.2183 亿美元，到 2026 年将成长至 1.4471 亿美元，到 2032 年将达到 2.986 亿美元，年复合成长率为 13.66%。

主要市场统计数据
基准年 2025 1.2183亿美元
预计年份：2026年 1.4471亿美元
预测年份 2032 2.986亿美元
复合年增长率 (%) 13.66%

针对神经性厌食症的综合框架，重点关注综合临床需求、发展阶段适宜的反应以及旨在改善患者预后的不断发展的治疗途径。

神经性厌食症是严重营养不良和根深蒂固的心理模式的结合，是行为医学领域最棘手、最复杂的挑战之一，需要协调一致的临床方法。近年来，临床实践和政策趋势提高了人们对该疾病长期致残性的认识，并强调了建立涵盖急性期、过渡时期和社区环境的综合护理路径的必要性。过去十年，临床医生和医疗保健系统越来越重视早期发现、家庭参与的照护模式以及衔接医疗稳定性、营养復健和针对性心理治疗的多学科干预措施。

科技采纳、早期疗育策略和保险公司主导的整合如何重新定义临床环境中护理路径和治疗的强度。

随着临床实践、技术和政策的交汇融合，厌食症的治疗方案和患者体验发生了翻天覆地的变化。远端医疗的扩展已从疫情期间的临时措施转变为与线下诊疗相辅相成的常态化模式。这确保了患者在不同距离下都能获得持续的医疗服务，并改善了服务不足地区患者的就医途径。同时，数位化评估工具和远距监测平台帮助临床医生在两次就诊之间追踪患者的生理参数和症状进展，从而在治疗的关键早期阶段实现更及时的干预并降低风险。

关税政策变化对供应链、临床试验物流和筹资策略的影响，以及对神经性厌食症专科治疗的连续性和成本的影响。

关税政策和跨境贸易趋势的变化会对供应链、药品进口以及医疗服务中使用的专用医疗设备的成本结构产生下游影响。对于依赖进口营养产品、医疗监测设备或特殊配方的医疗机构而言，关税波动会影响筹资策略和库存管理，迫使各机构重新评估其采购结构和库存缓衝，以维持医疗服务的连续性。医疗系统和独立医疗机构正在透过扩大供应商选择范围、尽可能增加在地采购以及协商更灵活的合约条款来应对关税波动带来的风险。

透过结合治疗环境、治疗方法、医疗保健提供者类型和发展阶段等因素进行细分，我们利用相关洞察，实施差异化的护理路径，以取得更好的治疗效果。

对不同治疗类型间护理连续性的分析揭示了不同的资源和临床负荷模式，每种模式都需要不同的营运应对措施。日间治疗计画、住院治疗和住宅照护都需要独特的人员编制模式、临床管治和医疗监测通讯协定。标准化的交接流程和通用的疗效评估指标能够有效减少病患在不同照护等级间转换时所出现的临床挫折。相较之下，治疗方法的差异则影响临床重点和训练需求。营养咨询是体重恢復和饮食支持的基础；药物治疗（包括选择性使用非典型抗精神病药物和选择性血清素再回收抑制剂）用于治疗合併症；心理治疗（透过认知行为疗法、家庭疗法和人际关係疗法）则用于治疗疾病的认知和关係因素。

从区域观点探讨临床基础设施、文化动态和政策框架如何影响饮食障碍照护的取得、服务设计和创新。

区域动态影响着从临床文化到法律规范和报销实践的方方面面，导致服务可近性和护理模式存在区域差异。儘管强大的研究基础设施、集中的卓越临床中心和不断发展的支付模式推动了美洲地区整合式照护路径的创新，但农村和都市区的医疗服务取得仍然存在差距。这些地区的医疗服务提供者正越来越多地采用远端医疗和协作式护理模式，以将其专业知识扩展到社区，而支付方也在探索以价值为基础的合同，以奖励持续康復和减少医疗併发症。

评估将整合系统、专科诊所、远端医疗平台和临床开发人员聚集在一起，以提供多学科协作护理的组织环境。

参与神经性厌食症治疗的组织生态系统涵盖了综合医疗保健系统、专业行为医学诊所、远端医疗平台以及提供监测和症状管理支援工具的製药和医疗设备研发公司。医疗保健系统和医院作为医疗稳定和复杂合併症管理中心，通常与专科诊所合作，以确保心理社会照护的连续性。专科诊所将专业知识集中于由註册营养师、心理学家、精神科医生和执业护士组成的多学科护理团队，并经常制定可在整个服务系统中复製的标准化护理路径。

医疗保健主管可采取的策略重点是扩大容量、整合远端医疗、加强采购系统和建立以结果主导的临床管治。

致力于提升神经性厌食症服务水准的领导者应优先考虑扩大临床服务能力，同时确保服务品质和连续性。首先，应投资于人力资源开发，重点为包括医生、註册营养师、心理健康临床医生和护理协调员在内的多学科团队提供基于能力的培训，并在每个护理阶段建立标准化的过渡通讯协定，以降低过渡风险。其次，应策略性地整合远端医疗，以扩大专科护理服务的范围，并实现分阶段护理模式。具体而言，应将高强度的线下治疗项目与线上追踪和看护者训练相结合，以维持治疗效果并降低再入院率。

我们采用高度透明、多方面的调查方法，结合文献整合、专家访谈和营运数据，得出基于临床证据的、可操作的见解。

本研究透过系统性文献回顾、专家访谈和跨学科证据评估，确保了其全面且具有临床基础的观点。同侪审查的临床试验、实践指南和共识声明为治疗方法建议提供了临床框架，而对临床医生、计画主管和保险公司的定性访谈则提供了关于营运环境、就医障碍和报销趋势的见解。来自服务提供者和技术供应商的数据有助于考察医疗服务模式的创新，特别是远端医疗和远端监测的作用。

整合临床和营运重点，透过综合、发展阶段。

神经性厌食症的治疗正处于一个转折点，临床进展、创新服务模式和政策转变为改善治疗效果创造了机会，但也要求整个治疗链上采取策略性的组织应对措施。所需的应对措施很明确：优先考虑早期、家庭参与的干预措施，整合医疗和社会心理关怀，并利用远端医疗和数位监测来提高服务的可及性和连续性。同时，营运韧性，尤其是在采购和供应链规划方面，仍然至关重要，以防止可能阻碍復原的服务中断。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗类型分類的神经性厌食症市场

  • 日间治疗项目
  • 住院治疗
  • 居住治疗

第九章 神经性厌食症的市场治疗方法

  • 营养咨询
  • 药物治疗
    • 非典型抗精神病药物
    • 选择性血清素再回收抑制剂
  • 心理治疗
    • 认知行为疗法
    • 家庭治疗
    • 人际关係疗法

第十章：神经性厌食症市场：依年龄组别划分

  • 青年
  • 成人
  • 儿童

第十一章 神经性厌食症市场：依最终用户划分

  • 医院
  • 专科诊所
  • 远端医疗提供者

第十二章 神经性厌食症市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 神经性厌食症市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 神经性厌食症市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国厌食症市场

第十六章：中国厌食症市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Acadia Healthcare Company, Inc.
  • Alkermes plc
  • Amgen Inc.
  • Biohaven Pharmaceuticals
  • Eating Recovery Center, LLC
  • Hologic, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mindstrong Health
  • Monte Nido & Affiliates, LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Priory Group Ltd
  • PsychoGenics Inc.
  • Rogers Behavioral Health
  • Sanofi SA
  • Sumitomo Pharma America, Inc.
  • Takeda Pharmaceutical Company Limited
  • The Renfrew Center, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Universal Health Services, Inc.
  • Walden Behavioral Care, Inc.
Product Code: MRR-1A1A064C0422

The Anorexia Nervosa Market was valued at USD 121.83 million in 2025 and is projected to grow to USD 144.71 million in 2026, with a CAGR of 13.66%, reaching USD 298.60 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 121.83 million
Estimated Year [2026] USD 144.71 million
Forecast Year [2032] USD 298.60 million
CAGR (%) 13.66%

A comprehensive framing of anorexia nervosa that highlights integrated clinical imperatives, developmental tailoring, and the evolving delivery pathways for improved patient outcomes

Anorexia nervosa presents one of the most persistent and complex challenges in behavioral health, combining severe nutritional compromise with entrenched psychological patterns that demand coordinated clinical responses. Recent clinical practice and policy developments have heightened awareness of the condition's long-term morbidity and the need for integrated pathways across acute, intermediate, and community settings. Over the past decade clinicians and health systems have increasingly prioritized earlier identification, family-inclusive models of care, and multidisciplinary interventions that bridge medical stabilization, nutritional rehabilitation, and targeted psychotherapy.

This executive summary synthesizes clinically relevant evidence and service-delivery trends to support decision-makers in healthcare delivery, policy, and life sciences. It focuses on the modalities that shape care access and quality, including treatment settings, therapy approaches, provider types, and age-specific adaptations. While clinical nuance varies by patient presentation, common themes emerge: the imperative of tailoring interventions to developmental stage, the critical role of coordinated medical oversight during weight restoration, and the centrality of psychosocial therapies to sustain recovery. In addition, evolving care delivery mechanisms and payer interactions are influencing how services are organized and reimbursed, with implications for clinical outcomes and operational sustainability.

Taken together, these considerations underscore the need for strategic investments in workforce training, care integration, and evidence-based program design to meet rising clinical complexity and evolving patient expectations.

How technological adoption, earlier intervention strategies, and payer-driven integration are redefining care pathways and treatment intensity across clinical settings

The landscape of anorexia nervosa care has shifted markedly as clinical practice, technology, and policy intersect to reshape treatment trajectories and patient experience. Telehealth expansion has moved from a pandemic-era stopgap to a durable modality that augments in-person care, enabling continuity for patients across distances and improving access for those in underserved regions. Concurrently, digital assessment tools and remote monitoring platforms support clinicians in tracking physiological parameters and symptom trajectories between visits, which in turn informs more timely interventions and reduces risk during the critical early phases of treatment.

At the same time, clinical paradigms have evolved to favor earlier engagement and family-inclusive strategies, driven by evidence supporting improved outcomes with developmentally attuned interventions. Psychotherapeutic modalities such as cognitive behavioral therapy and family-based approaches have seen refinements in protocols and wider adoption across settings, while nutritional counseling has been integrated more closely with medical oversight to accelerate stabilization without compromising psychological work. Pharmacotherapy continues to play a secondary yet important role, primarily for co-occurring psychiatric symptoms and selective indications; the use of atypical antipsychotics and selective serotonin reuptake inhibitors remains targeted and adjunctive rather than primary.

These transformative shifts have been reinforced by payer and policy adjustments that emphasize stepped-care pathways, quality metrics tied to clinical outcomes, and incentives for integrated behavioral health models. As a result, providers and system leaders are redesigning care pathways to balance intensity, accessibility, and quality across day treatment programs, inpatient hospitalization, and residential treatment modalities.

Impacts of evolving tariff policies on supply chains, clinical trials logistics, and procurement strategies that influence continuity and cost of specialized anorexia nervosa care

Changes in tariff policy and cross-border trade dynamics have downstream effects on supply chains, pharmaceutical imports, and the cost structure of specialized medical equipment used in care delivery. For providers reliant on imported nutritional products, medical monitoring devices, or specialty formulations, shifts in tariffs alter procurement strategies and inventory management, prompting organizations to reassess sourcing arrangements and inventory buffers to maintain continuity of care. Health systems and independent providers are responding by broadening supplier panels, increasing local procurement where feasible, and negotiating more flexible contracting terms to mitigate exposure to tariff volatility.

Pharmaceutical development and clinical trials can also be affected indirectly through changes in the cost base for importing investigational supplies and equipment. Clinical program managers and sponsors are integrating tariff considerations into trial budgeting and logistics planning to avoid disruptions to dosing regimens or monitoring schedules. In tandem, international collaborations for research and training may require recalibration of resource flows and event planning when cross-border expenses shift.

Importantly, shifts in trade policy compel payer and provider procurement teams to adopt scenario planning that anticipates periods of price instability, with an emphasis on maintaining clinical quality and uninterrupted access to essential supplies. By embedding tariff sensitivity into supply-chain governance and contracting, organizations can preserve treatment continuity and protect vulnerable patients from gaps in care that could adversely affect clinical recovery trajectories.

Segmentation-driven insights that align treatment setting, therapeutic modality, provider type, and developmental stage to operationalize differentiated care pathways for better outcomes

Disaggregating the care continuum by treatment type reveals distinct resource and clinical intensity profiles that require differentiated operational responses. Day Treatment Program, Inpatient Hospitalization, and Residential Treatment each demand specific staffing models, clinical governance, and medical monitoring protocols; transitioning patients between these levels of care benefits from standardized handoffs and shared outcome metrics to minimize clinical regression. By contrast, therapy modality distinctions shape the clinical focus and training needs: Nutritional Counseling serves as the backbone of weight restoration and meal support, Pharmacotherapy-used selectively and inclusive of Atypical Antipsychotics and Selective Serotonin Reuptake Inhibitors-targets comorbid symptoms, and Psychotherapy-implemented through Cognitive Behavioral Therapy, Family Based Therapy, and Interpersonal Therapy-addresses the cognitive and relational drivers of illness.

End-user segmentation highlights where investment and innovation can have immediate operational impact. Hospitals deliver integrated medical stabilization and psychiatric liaison services; Specialized Clinics concentrate on multidisciplinary eating-disorder expertise and programmatic continuity; and Telehealth Providers extend reach and continuity through virtual platforms that support outpatient follow-up and caregiver coaching. Each end-user type faces unique challenges in workforce development, reimbursement navigation, and quality assurance.

Age-based considerations are equally critical: adolescents often require family-centered interventions and coordination with schools, adults may present with longer illness duration and comorbidities necessitating coordinated medical and psychiatric management, and children call for developmentally calibrated approaches that balance parental involvement with age-appropriate engagement. By weaving together treatment type, therapy approach, provider setting, and age group considerations, stakeholders can design care pathways that align clinical intensity with patient needs and system capacity.

A regional perspective on how clinical infrastructure, cultural dynamics, and policy frameworks shape access, service design, and innovation in eating-disorder care

Regional dynamics shape everything from clinical culture to regulatory frameworks and reimbursement practices, driving variation in service availability and care models across geographies. In the Americas, robust research infrastructure, concentrated centers of clinical excellence, and evolving payer models have driven innovations in integrated care pathways, while persistent access gaps remain in rural and underserved urban communities. Providers in this region increasingly adopt telehealth and collaborative care arrangements to extend specialty expertise into community settings, and payers are exploring value-based arrangements that reward sustained recovery and reduced medical complications.

Across Europe, Middle East & Africa, heterogeneity in healthcare systems produces a wide range of access and delivery models. Some European countries have well-established national pathways and funding mechanisms for specialized eating-disorder services, whereas other jurisdictions contend with limited specialist capacity and stigma-related barriers to care. In parts of the Middle East and Africa, community outreach and task-shared models are gaining traction to address shortages in specialist clinicians, and partnerships between public and private providers are emerging to expand access.

In the Asia-Pacific region, growing clinical recognition and investment in mental health services are expanding the landscape of care, yet cultural factors and resource constraints shape help-seeking behaviors and service design. Telehealth and digital education initiatives are accelerating uptake, while localized adaptations of evidence-based therapies aim to improve acceptability and adherence. Across all regions, cross-border collaboration in research, training, and guideline development offers opportunities to disseminate best practices and reduce fragmentation in service delivery.

Assessing the organizational landscape where integrated systems, specialized clinics, telehealth platforms, and clinical developers converge to deliver multidisciplinary care

The ecosystem of organizations active in anorexia nervosa care spans integrated health systems, specialized behavioral health clinics, telehealth platforms, and pharmaceutical and device developers that supply adjunctive tools for monitoring and symptom management. Health systems and hospitals serve as hubs for medical stabilization and complex comorbidity management, often partnering with specialized clinics to ensure continuity of psychosocial care. Specialized clinics concentrate expertise in multidisciplinary care teams, including dietitians, psychologists, psychiatrists, and nurse practitioners, and they often develop programmatic pathways that can be replicated across service lines.

Telehealth providers have scaled models for virtual therapy, caregiver coaching, and stepped-care follow-up, reducing geographic barriers to specialist consultation and enabling more frequent touchpoints that support adherence. Meanwhile, pharmaceutical companies and clinical-stage developers continue to explore pharmacologic approaches for symptom management and comorbidities, recognizing that medication remains adjunctive to core psychosocial and nutritional interventions. Device and digital health vendors are introducing remote monitoring tools and adherence supports that facilitate earlier clinical intervention and more granular outcome tracking.

From an operational perspective, collaboration across these organization types is critical: integrated pathways between hospitals, specialized clinics, and telehealth platforms reduce fragmentation; partnerships with technology vendors enhance monitoring capabilities; and strategic alignment with clinical researchers accelerates the translation of evidence into practice. Stakeholders that cultivate these collaborative linkages position themselves to deliver more coordinated, patient-centered care.

Actionable strategic priorities for healthcare executives to scale capacity, integrate telehealth, fortify procurement, and embed outcome-driven clinical governance

Leaders seeking to strengthen anorexia nervosa services should prioritize actions that scale clinical capacity while safeguarding quality and continuity. First, invest in workforce development that emphasizes competency-based training for multidisciplinary teams, including physicians, dietitians, mental health clinicians, and care coordinators, and embed standardized handoff protocols across levels of care to reduce risk during transitions. Second, integrate telehealth strategically to extend specialty reach and enable stepped-care models, combining high-intensity in-person programs with virtual follow-up and caregiver coaching to sustain gains and reduce readmissions.

Third, develop robust supply-chain and procurement strategies that anticipate cost volatility and ensure uninterrupted access to essential nutritional products and monitoring equipment. Fourth, strengthen measurement systems that track clinical outcomes, functional recovery, and patient experience, and use these metrics to inform continuous improvement and payer negotiations. Fifth, foster cross-sector partnerships with academic centers and clinical researchers to participate in trials and translational studies that expand treatment options and refine best practices.

Finally, prioritize equity and cultural competence in program design by adapting therapies and outreach approaches to meet the needs of diverse populations and reduce stigma-related barriers. By advancing these priorities in parallel-workforce, telehealth integration, procurement resilience, measurement, research partnerships, and equity-organizations can build sustainable programs that deliver measurable clinical benefit and improve long-term recovery trajectories.

A transparent multi-source methodology combining literature synthesis, expert interviews, and operational data to derive clinically grounded and implementable insights

This research synthesis combines systematic literature review, expert interviews, and cross-disciplinary evidence appraisal to ensure a comprehensive and clinically grounded perspective. Peer-reviewed clinical trials, practice guidelines, and consensus statements provided the clinical scaffold for therapy and treatment recommendations, while qualitative interviews with clinicians, program directors, and payers furnished operational context and insights into barriers to access and reimbursement dynamics. Data from service providers and technology vendors informed considerations of care delivery innovation, particularly the role of telehealth and remote monitoring.

Analytic rigor was maintained through triangulation of sources and iterative validation with subject-matter experts, including clinicians experienced in adolescent and adult eating-disorder care, dietitians, and clinical operations leaders. Where primary evidence was limited-such as in novel digital interventions or emerging procurement impacts-interpretation emphasized pragmatic implications rather than definitive claims, and uncertainty was explicitly noted. Ethical and methodological standards guided the inclusion of studies, with attention to study quality, sample characteristics, and generalizability to routine clinical settings.

The synthesis deliberately avoided speculative financial estimations and instead prioritized clinically meaningful patterns, operational levers, and regional considerations to support strategic decision-making by providers, payers, and commercial partners.

Synthesis of clinical and operational priorities that reinforce integrated, developmentally informed, and resilient approaches to delivering high-quality anorexia nervosa care

Anorexia nervosa care is at an inflection point where clinical advances, delivery-model innovation, and policy shifts create opportunities to improve outcomes but also demand strategic responses from organizations across the care continuum. The imperative is clear: prioritize early and family-inclusive interventions, integrate medical and psychosocial care, and leverage telehealth and digital monitoring to augment access and continuity. Concurrently, operational resilience-particularly in procurement and supply-chain planning-remains essential to prevent service interruptions that can undermine recovery.

Stakeholders that invest in workforce competencies, standardized care pathways, and cross-sector partnerships will be better positioned to translate evidence into routine practice and to meet diverse patient needs across developmental stages. Regional differences remain salient, and the most effective programs will adapt global best practices to local cultural, regulatory, and resource realities. Ultimately, progress will depend on aligning clinical excellence with sustainable operations and payer engagement so that high-quality, accessible care becomes the norm rather than the exception.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anorexia Nervosa Market, by Treatment Type

  • 8.1. Day Treatment Program
  • 8.2. Inpatient Hospitalization
  • 8.3. Residential Treatment

9. Anorexia Nervosa Market, by Therapy Type

  • 9.1. Nutritional Counseling
  • 9.2. Pharmacotherapy
    • 9.2.1. Atypical Antipsychotics
    • 9.2.2. Selective Serotonin Reuptake Inhibitors
  • 9.3. Psychotherapy
    • 9.3.1. Cognitive Behavioral Therapy
    • 9.3.2. Family Based Therapy
    • 9.3.3. Interpersonal Therapy

10. Anorexia Nervosa Market, by Age Group

  • 10.1. Adolescents
  • 10.2. Adults
  • 10.3. Children

11. Anorexia Nervosa Market, by End User

  • 11.1. Hospitals
  • 11.2. Specialized Clinics
  • 11.3. Telehealth Providers

12. Anorexia Nervosa Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anorexia Nervosa Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anorexia Nervosa Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anorexia Nervosa Market

16. China Anorexia Nervosa Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Acadia Healthcare Company, Inc.
  • 17.6. Alkermes plc
  • 17.7. Amgen Inc.
  • 17.8. Biohaven Pharmaceuticals
  • 17.9. Eating Recovery Center, LLC
  • 17.10. Hologic, Inc.
  • 17.11. Johnson & Johnson
  • 17.12. Merck & Co., Inc.
  • 17.13. Mindstrong Health
  • 17.14. Monte Nido & Affiliates, LLC
  • 17.15. Otsuka Pharmaceutical Co., Ltd.
  • 17.16. Pfizer Inc.
  • 17.17. Priory Group Ltd
  • 17.18. PsychoGenics Inc.
  • 17.19. Rogers Behavioral Health
  • 17.20. Sanofi S.A.
  • 17.21. Sumitomo Pharma America, Inc.
  • 17.22. Takeda Pharmaceutical Company Limited
  • 17.23. The Renfrew Center, Inc.
  • 17.24. Tonix Pharmaceuticals Holding Corp.
  • 17.25. Universal Health Services, Inc.
  • 17.26. Walden Behavioral Care, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)